270 related articles for article (PubMed ID: 32575682)
1. Drug Sequestration in Lysosomes as One of the Mechanisms of Chemoresistance of Cancer Cells and the Possibilities of Its Inhibition.
Hraběta J; Belhajová M; Šubrtová H; Merlos Rodrigo MA; Heger Z; Eckschlager T
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575682
[TBL] [Abstract][Full Text] [Related]
2. Lysosomes as mediators of drug resistance in cancer.
Zhitomirsky B; Assaraf YG
Drug Resist Updat; 2016 Jan; 24():23-33. PubMed ID: 26830313
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis.
Zhitomirsky B; Assaraf YG
Oncotarget; 2017 Jul; 8(28):45117-45132. PubMed ID: 28187461
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.
Yamagishi T; Sahni S; Sharp DM; Arvind A; Jansson PJ; Richardson DR
J Biol Chem; 2013 Nov; 288(44):31761-71. PubMed ID: 24062304
[TBL] [Abstract][Full Text] [Related]
5. Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells.
You H; Jin J; Shu H; Yu B; De Milito A; Lozupone F; Deng Y; Tang N; Yao G; Fais S; Gu J; Qin W
Cancer Lett; 2009 Jul; 280(1):110-9. PubMed ID: 19299075
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.
Ouar Z; Bens M; Vignes C; Paulais M; Pringel C; Fleury J; Cluzeaud F; Lacave R; Vandewalle A
Biochem J; 2003 Feb; 370(Pt 1):185-93. PubMed ID: 12435274
[TBL] [Abstract][Full Text] [Related]
7. Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells.
Hrabeta J; Groh T; Khalil MA; Poljakova J; Adam V; Kizek R; Uhlik J; Doktorova H; Cerna T; Frei E; Stiborova M; Eckschlager T
Int J Oncol; 2015 Sep; 47(3):971-80. PubMed ID: 26134421
[TBL] [Abstract][Full Text] [Related]
8. The role of endolysosomal trafficking in anticancer drug resistance.
Hussein NA; Malla S; Pasternak MA; Terrero D; Brown NG; Ashby CR; Assaraf YG; Chen ZS; Tiwari AK
Drug Resist Updat; 2021 Jul; 57():100769. PubMed ID: 34217999
[TBL] [Abstract][Full Text] [Related]
9. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance.
Zhitomirsky B; Assaraf YG
Oncotarget; 2015 Jan; 6(2):1143-56. PubMed ID: 25544758
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal Fusion: An Efficient Mechanism Increasing Their Sequestration Capacity for Weak Base Drugs without Apparent Lysosomal Biogenesis.
Skoupa N; Dolezel P; Mlejnek P
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31947839
[TBL] [Abstract][Full Text] [Related]
11. Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.
Al-Akra L; Bae DH; Sahni S; Huang MLH; Park KC; Lane DJR; Jansson PJ; Richardson DR
J Biol Chem; 2018 Mar; 293(10):3562-3587. PubMed ID: 29305422
[TBL] [Abstract][Full Text] [Related]
12. Can image analysis provide evidence that lysosomal sequestration mediates daunorubicin resistance?
Mlejnek P; Havlasek J; Pastvova N; Dolezel P
Chem Biol Interact; 2020 Aug; 327():109138. PubMed ID: 32485151
[TBL] [Abstract][Full Text] [Related]
13. The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane.
Stark M; Silva TFD; Levin G; Machuqueiro M; Assaraf YG
Cells; 2020 Apr; 9(5):. PubMed ID: 32349204
[TBL] [Abstract][Full Text] [Related]
14. Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer.
Shirbhate E; Singh V; Mishra A; Jahoriya V; Veerasamy R; Tiwari AK; Rajak H
Mini Rev Med Chem; 2024 Feb; ():. PubMed ID: 38343053
[TBL] [Abstract][Full Text] [Related]
15. Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity.
Zhitomirsky B; Yunaev A; Kreiserman R; Kaplan A; Stark M; Assaraf YG
Cell Death Dis; 2018 Dec; 9(12):1191. PubMed ID: 30546014
[TBL] [Abstract][Full Text] [Related]
16. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
Niikura K; Takano M; Sawada M
Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
[TBL] [Abstract][Full Text] [Related]
17. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump.
Fan S; Niu Y; Tan N; Wu Z; Wang Y; You H; Ke R; Song J; Shen Q; Wang W; Yao G; Shu H; Lin H; Yao M; Zhang Z; Gu J; Qin W
Oncogene; 2013 Mar; 32(13):1682-90. PubMed ID: 22580606
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors may reduce tumour resistance.
De Milito A; Fais S
Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
[TBL] [Abstract][Full Text] [Related]
19. V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.
Kubisch R; Fröhlich T; Arnold GJ; Schreiner L; von Schwarzenberg K; Roidl A; Vollmar AM; Wagner E
Int J Cancer; 2014 May; 134(10):2478-88. PubMed ID: 24166050
[TBL] [Abstract][Full Text] [Related]
20. Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.
Seebacher NA; Lane DJ; Jansson PJ; Richardson DR
J Biol Chem; 2016 Feb; 291(8):3796-820. PubMed ID: 26601947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
